Alcon

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.

TrueVision Systems, Inc. specializes in developing advanced three-dimensional (3D) visualization systems aimed at enhancing surgical procedures, particularly in microsurgery and neurosurgery. Founded in 2003 and based in Santa Barbara, California, the company offers a range of products, including high-definition digital imaging systems, software for surgical guidance, and tools for intra-operative positioning of lenses. TrueVision's flagship product, the TrueVision 3DHD vision system, allows surgeons to view the surgical field in real-time on a 3D display, improving visualization and efficiency during operations. The company's technology is based on patented innovations in digital stereoscopic imaging and is utilized across various surgical disciplines. TrueVision also licenses its technology for broader applications, contributing to improved surgical outcomes and educational practices. The founder, Dr. Michael Weissman, is recognized as a leading expert in the field, driving the company's mission to enhance digital visualization in surgery. As of 2018, TrueVision operates as a subsidiary of Alcon, Inc.

Tear Film Innovations (tearfilm.com) has developed the iLux® Dry Eye Treatment System, a breakthrough medical device for treating evaporative dry eye. Evaporative dry eye is the most prevalent form of dry eye and affects more than 330M people worldwide. The FDA-cleared, handheld iLux device enables an eye care professional to evaluate and treat dry eye patients in less than ten minutes.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

SensoMotoric Instruments GmbH is a leading developer and marketer of application-specific gaze and eye tracking systems, original equipment manufacturer solutions, and medical applications. Established in 1991 and headquartered in Teltow, Germany, with additional offices in Berlin and Boston, the company offers a range of products tailored for various sectors, including market research, neuromarketing, neuroscience, ophthalmology, and education. Their offerings include eye tracking platforms for desktop and mobile devices, wearable eye tracking glasses, and solutions for virtual and augmented reality applications. SensoMotoric Instruments serves a global customer base and is recognized for its innovative products and services, with over 6,000 eye tracker systems operational worldwide.

Alcon LenSx specializes in the manufacturing of advanced surgical lasers designed for cataract surgery. The company offers a next-generation femtosecond laser system that operates inside the eye to facilitate cataract removal. This innovative technology not only focuses on cataract repair but also integrates multiple refractive surgical procedures related to the cornea and lens. Alcon LenSx is committed to enhancing surgical precision and improving patient outcomes through its cutting-edge laser solutions.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

Wavelight specializes in the design, manufacture, and marketing of advanced laser systems for various medical, aesthetic, and industrial applications. Its medical focus encompasses ophthalmology, dermatology, and urology, with a particular emphasis on correcting vision defects. The company's innovative technologies include electronic guidance systems for the precise positioning of intraocular lenses and eye-tracking systems specifically for laser procedures. These advancements enhance the accuracy and reproducibility of refractive cataract surgeries, ultimately improving patient outcomes.